
Zantrene AML Trial at Chaim Sheba, Israel Advances to Phase 2
Phase 1b dose escalation stage of the Phase 1b/2 Zantrene study in AML has completed…
Welcome to our Investor page. Here you will find information on the latest ASX announcements, investor presentations and other shareholder information on Race Oncology.
Welcome to our Investor page. Here you will find information on the latest ASX announcements, investor presentations and other shareholder information on Race Oncology.
Share Price
Phase 1b dose escalation stage of the Phase 1b/2 Zantrene study in AML has completed…
Race Oncology Limited (“Race”) is pleased to announce it has received Research Governance Office (RGO)…
March-2022-Quarterly-Activity-Report-and-Appendix-4CDownload
Race Oncology CSO Dr Daniel Tillett talks to WIN Television News about Race Oncology’s research…
6 April 2022 – Race Oncology Limited (“Race”) is pleased to announce it has receivedhuman…
Zantrene-Highly-Effective-in-a-Mouse-Model-of-Extramedullary-AMLDownload